Accessibility StatementSkip Navigation BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston. The companies aim to improve the diagnosis and treatment of breast and prostate cancer by developing an optimized next generation sequencing (NGS) solution that leverages SOPHiA GENETICS's AI algorithms to dete ...

Accessibility StatementSkip Navigation Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) (Alnylam) as a member of the ...

Accessibility StatementSkip Navigation NASDAQ | TSX: ACB About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniM ...

核心观点 - Denifanstat (ASC40) 在治疗中重度痤疮的III期临床试验中达成所有主要、关键次要及次要疗效终点 并展现出良好的安全性与耐受性特征[1][4][11] - 公司正与中国国家药品监督管理局进行新药上市申请前咨询 计划在完成咨询后提交Denifanstat (ASC40)的上市申请[2][11] 临床试验设计 - 该III期临床试验为随机、双盲、安慰剂对照、多中心临床研究 在中国招募480名中重度痤疮患者 按1:1比例随机分配至Denifanstat组(50mg 每日一次口服)或安慰剂组 治疗周期为12周[4] - 主要终点包括治疗成功率(IGA评分达到0或1且较基线下降至少2分)、总皮损计数(TLC)较基线变化百分比及炎症性皮损计数(ILC)较基线变化百分比[5][8] 疗效结果 - 治疗4周后 Denifanstat组在多个疗效终点上已显示出统计学显著改善(p<0.05) 包括治疗成功率、TLC、ILC及非炎症性皮损计数(NILC)[6] - 治疗12周后 Denifanstat组治疗成功率达33.17% 显著高于安慰剂组的14.58%(p<0.0001)[6] - TLC较基线减少百分比达57.38% 显著高于安慰剂组的35.42%(p<0.0001)[6] - ILC较基线减少百分比达63.45% 显著高于安慰剂组的43.21%(p<0.0001)[6] - NILC较基线减少百分比达51.85% 显著高于安慰剂组的28.94%(p<0.0001)[6] 安全性特征 - Denifanstat组治疗期间不良事件(TEAEs)发生率为58.6% 与安慰剂组的56.3%相当[1][9] - 大多数TEAEs为轻度(1级)或中度(2级) 无药物相关的3级或4级TEAEs 无药物相关的严重不良事件(SAEs) 无死亡报告 无因药物导致的永久性治疗中止或退出[9] - 发生率超过5%的TEAEs包括皮肤干燥(6.3% vs 2.9%)和干眼症(5.9% vs 3.8%)[9] 公司背景与合作协议 - Ascletis Pharma Inc是一家专注于代谢疾病治疗药物开发与商业化的生物技术公司 利用其专有人工智能辅助结构基于药物发现平台(AISBDD)和超长效平台(ULAP)开发了多个候选药物[13] - 公司从Sagimet Biosciences Inc获得Denifanstat (ASC40)在大中华区的独家权利[12] 数据发布与行业活动 - III期研究结果于2025年9月17日在欧洲皮肤病与性病学会(EADV)年会最新突破性新闻环节进行口头报告[3] - 详细数据可在公司网站获取[10]

Accessibility StatementSkip Navigation Initially launched in 2012 in Vienna, Austria, by people with diabetes for people with diabetes, the mySugr app is today available in over 84 countries and 25 languages, enabling users to manage key therapy data. mySugr Glucose Insights, the Accu-Chek SmartGuide integration with the mySugr app, just received CE mark approval and is set to launch in the first countries later this year. Users can view and analyse their CGM glucose values and predictions in one place, alo ...

公司活动安排 - 公司管理层将于2025年9月24日东部时间上午8:00在Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum上进行演讲 [1] - 活动将通过公司官网投资者关系栏目进行直播和回放 回放内容将在活动结束后保留至少30天 [1] 公司业务与技术 - 公司使命是在癌症可治愈的早期阶段进行检测 致力于通过减轻全球癌症负担 [2] - 核心技术平台基于靶向甲基化检测 结合下一代测序技术、大规模临床研究以及先进的机器学习、软件和自动化技术 [2] - 平台应用涵盖筛查和精准肿瘤学的连续护理 包括对有症状患者进行多癌种早期检测、风险分层、微小残留病灶检测、生物标志物亚型分型以及治疗和复发监测 [2] 公司基本信息 - 公司总部位于加利福尼亚州门洛帕克 在华盛顿特区、北卡罗来纳州和英国设有办事处 [2] - 公司股票在纳斯达克交易所上市 交易代码为GRAL [1][2][4][5]